https://www.nature.com/articles/d41586-024-01566-8 Skip to main content Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript. Advertisement Advertisement Nature * View all journals * Search * Log in * Explore content * About the journal * Publish with us * Subscribe * Sign up for alerts * RSS feed 1. nature 2. news 3. article * NEWS * 29 May 2024 'Smart' antibiotic can kill deadly bacteria while sparing the microbiome Compound called lolamicin targets a group of harmful microbes but does not disturb those that live peacefully in the gut. By * Fred Schwaller 1. Fred Schwaller View author publications You can also search for this author in PubMed Google Scholar * Twitter * Facebook * Email False-colour scanning electron micrograph of a colony of the bacteria Klebsiella pneumonia. Gram-negative bacteria such as Klebsiella pneumoniae (artificially coloured) are often resistant to multiple antibiotics, but they succumb to a new compound called lolamicin.Credit: Dr Tony Brain/ Science Photo Library They are the stuff of medical nightmares. Pathogens classified as Gram-negative bacteria are often hardy, virulent and quick to evolve resistance to antibiotics. Only a few drugs can knock them out, and these also destroy beneficial gut bacteria. Now scientists have developed an antibiotic that kills pathogenic Gram-negative bacteria -- even those resistant to many other drugs -- without impairing the gut microbiome. So far, it has been studied only in mice, but if the compound works in humans, "it could help us dramatically", says Sebastian Hiller, a structural biologist at the University of Basel in Switzerland who was not involved in the research. However, there is a caveat, he says: the compound's usefulness "depends on whether bacteria will develop resistance to it in the long run". The study appears today in Nature. Small but deadly Gram-negative bacteria include public-health villains such as Escherichia coli and Klebsiella pneumoniae. They cause diseases ranging from salmonella to cholera, and can trigger sepsis, a potentially lethal immune-system response to infection. The bacteria have "multiple barriers that prevent antibiotic penetration", says molecular biologist Zemer Gitai at Princeton University in New Jersey, who was not involved in the research. As a result, there are almost no antibiotics that specifically target Gram-negative bacteria. The few drugs that do also wreak havoc with the gut microbiome, allowing potentially deadly pathogens such as Clostridioides difficile to take over. [d41586-024] UTIs make life miserable -- scientists are finding new ways to tackle them To find a way around the bacteria's defences, the study's authors started with compounds that don't kill the bacteria but are known to inhibit the 'Lol system', a group of proteins that is exclusive to Gram-negative bacteria. Tinkering with those compounds produced one that the researchers called lolamicin, which "selectively kills pathogenic bacteria over non-pathogenic bacteria based on differences in Lol proteins between these bacteria", says study co-author Paul Hergenrother, a chemist at the University of Illinois at Urbana-Champaign. Lolamicin had anti-microbial effects against more than 130 multidrug-resistant strains of bacteria growing in laboratory dishes. Mice that developed blood stream infections after exposure to antibiotic-resistant bacteria all survived after being given lolamicin, whereas 87% of those that didn't receive the compound died within three days. The team also found that common antibiotics such as amoxicillin severely disrupted the animals' gut microbiome, which led to infections with C. difficile. By contrast, lolamicin treatment did not cause observable changes in the gut microbiome and spared mice from C. difficile infection. 'A long road' Gitai says that the study "proves the viability" of targeting the Lol system, but adds, "There is a long road from showing efficacy in mice to developing a drug for human use." Hiller also sounds a cautious note. The time from an antibiotic's discovery to its approval for clinical use can be more than two decades, "and there is not much money to be made with a novel antibiotic", he says. "Around ten to twenty new Gram-negative antibiotics have been discovered in the last ten years", he adds, but none has gained approval from the US Food and Drug Administration. doi: https://doi.org/10.1038/d41586-024-01566-8 References 1. Munoz, K. A. et al. Nature https://doi.org/10.1038/ s41586-024-07502-0 (2024). Article Google Scholar Download references Reprints and permissions Related Articles * [d41586-024] The staggering death toll of drug-resistant bacteria * [d41586-024] Three ways to combat antimicrobial resistance * [d41586-024] Can non-profits beat antibiotic resistance and soaring drug costs? * [d41586-024] Antibiotic resistance is a growing threat -- is climate change making it worse? * [d41586-024] UTIs make life miserable -- scientists are finding new ways to tackle them Subjects * Antibiotics * Microbiology * Drug discovery * Medical research Latest on: Antibiotics A Gram-negative-selective antibiotic that spares the gut microbiome A Gram-negative-selective antibiotic that spares the gut microbiome Article 29 MAY 24 Antibiotic resistance is a growing threat -- is climate change making it worse? Antibiotic resistance is a growing threat -- is climate change making it worse? News Feature 08 JAN 24 A new class of antibiotics is cause for cautious celebration -- but the economics must be fixed A new class of antibiotics is cause for cautious celebration -- but the economics must be fixed Editorial 03 JAN 24 Microbiology Transcriptional control of the Cryptosporidium life cycle Transcriptional control of the Cryptosporidium life cycle Article 29 MAY 24 A Gram-negative-selective antibiotic that spares the gut microbiome A Gram-negative-selective antibiotic that spares the gut microbiome Article 29 MAY 24 Nitrogen-hungry bacteria added to farm soil curb greenhouse-gas emissions Nitrogen-hungry bacteria added to farm soil curb greenhouse-gas emissions News & Views 29 MAY 24 Drug discovery Randomized trials of cancer drugs are for yesterday Randomized trials of cancer drugs are for yesterday Outlook 29 MAY 24 How antibody-drug conjugates aim to take down cancer How antibody-drug conjugates aim to take down cancer Outlook 29 MAY 24 Natural killer cells show their cancer-fighting worth Natural killer cells show their cancer-fighting worth Outlook 29 MAY 24 Nature Careers Jobs * Postdoctoral Associate - Amyloid Strain Differences in Alzheimer's Disease Houston, Texas (US) Baylor College of Medicine (BCM) [] * Postdoctoral Associate- Bioinformatics of Alzheimer's disease Houston, Texas (US) Baylor College of Medicine (BCM) [] * Postdoctoral Associate- Alzheimer's Gene Therapy Houston, Texas (US) Baylor College of Medicine (BCM) [] * Postdoctoral Associate Houston, Texas (US) Baylor College of Medicine (BCM) [] * KAUST Global Postdoctoral Fellowship The KAUST Global Fellowship Program is designed to attract emerging research leaders working across areas under the four research priorities of KAUST. Saudi Arabia (SA) King Abdullah University of Science and Technology (KAUST You have full access to this article via your institution. Download PDF Related Articles * [d41586-024] The staggering death toll of drug-resistant bacteria * [d41586-024] Three ways to combat antimicrobial resistance * [d41586-024] Can non-profits beat antibiotic resistance and soaring drug costs? * [d41586-024] Antibiotic resistance is a growing threat -- is climate change making it worse? * [d41586-024] UTIs make life miserable -- scientists are finding new ways to tackle them Subjects * Antibiotics * Microbiology * Drug discovery * Medical research Advertisement Sign up to Nature Briefing An essential round-up of science news, opinion and analysis, delivered to your inbox every weekday. Email address [ ] [ ] Yes! Sign me up to receive the daily Nature Briefing email. I agree my information will be processed in accordance with the Nature and Springer Nature Limited Privacy Policy. Sign up * Close Nature Briefing Sign up for the Nature Briefing newsletter -- what matters in science, free to your inbox daily. Email address [ ] Sign up [ ] I agree my information will be processed in accordance with the Nature and Springer Nature Limited Privacy Policy. Close Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing Explore content * Research articles * News * Opinion * Research Analysis * Careers * Books & Culture * Podcasts * Videos * Current issue * Browse issues * Collections * Subjects * Follow us on Facebook * Follow us on Twitter * Subscribe * Sign up for alerts * RSS feed About the journal * Journal Staff * About the Editors * Journal Information * Our publishing models * Editorial Values Statement * Journal Metrics * Awards * Contact * Editorial policies * History of Nature * Send a news tip Publish with us * For Authors * For Referees * Language editing services * Submit manuscript Search Search articles by subject, keyword or author [ ] Show results from [All journals] Search Advanced search Quick links * Explore articles by subject * Find a job * Guide to authors * Editorial policies Nature (Nature) ISSN 1476-4687 (online) ISSN 0028-0836 (print) nature.com sitemap About Nature Portfolio * About us * Press releases * Press office * Contact us Discover content * Journals A-Z * Articles by subject * protocols.io * Nature Index Publishing policies * Nature portfolio policies * Open access Author & Researcher services * Reprints & permissions * Research data * Language editing * Scientific editing * Nature Masterclasses * Research Solutions Libraries & institutions * Librarian service & tools * Librarian portal * Open research * Recommend to library Advertising & partnerships * Advertising * Partnerships & Services * Media kits * Branded content Professional development * Nature Careers * Nature Conferences Regional websites * Nature Africa * Nature China * Nature India * Nature Italy * Nature Japan * Nature Middle East * Privacy Policy * Use of cookies * Your privacy choices/Manage cookies * Legal notice * Accessibility statement * Terms & Conditions * Your US state privacy rights Springer Nature (c) 2024 Springer Nature Limited